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Abstract Several recent studies describing a solely vascular
presentation of cystathionine beta-synthase (CBS) deficiency
in adulthood prompted us to analyze the frequency of
patients manifesting with vascular complications in the
Czech Republic. Between 1980 and 2009, a total of 20
Czech patients with CBS deficiency have been diagnosed
yielding an incidence of 1:311,000. These patients were
divided into three groups based on symptoms leading to
diagnosis: those with vascular complications, with connec-
tive tissue manifestation and with neurological presentation.
A vascular event such as a clinical feature leading to
diagnosis of homocystinuria was present in five patients,
while two of them had no other symptoms typical for CBS
deficiency at the time of diagnosis. All patients with the
vascular manifestation were diagnosed only during the past
decade. The median age of diagnosis was 29 years in the
vascular, 11.5 years in the connective tissue and 4.5 years in
the neurological group. The ratio of pyridoxine responsive to
nonresponsive patients was higher in the vascular (4 of 5
patients) and connective tissue groups (6 of 7 patients) than
in the neurological group (2 of 8 patients). Mutation
c.833T>C (p.I278T) was frequent in patients with vascular
(6/10 alleles) and connective tissue presentation (8/14
alleles), while it was not present in patients with neurological
involvement (0/16 alleles). During the last decade, we have
observed patients with homocystinuria diagnosed solely
due to vascular events; this milder form of homocysti-
nuria usually manifests at greater ages, has a high ratio
of pyridoxine responsiveness/nonresponsiveness, and the
mutation c.833T>C (p.I278T) is often present.
Abbreviations
CBS Cystathionine beta-synthase
Introduction
Homocystinuria due to cystathionine β-synthase (CBS; EC
4.2.1.22) deficiency (OMIM# 236200) is the most common
inborn error of methionine metabolism (Mudd et al. 2001).
The disease was discovered in 1962, when mentally
retarded individuals were screened for abnormal excretion
of urinary amino acids. An accumulation of homocysteine
in tissues leading to the formation and urinary excretion of
homocysteine disulfide, homocystine, was observed
(Gerritsen et al. 1962), and subsequently CBS deficiency
hasbeenshownasthe causeofthedisease(Muddetal.1964).
The clinical phenotype of homocystinuria was largely
documented in the group of 629 patients by Mudd et al.
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DOI 10.1007/s10545-010-9146-y(1985). The most common symptoms include neurological
complications such as mental retardation and epilepsy,
marfanoid features with lens ectopia, and vascular changes
represented mostly by thromboembolic events. These
symptoms were present separately or in various combina-
tions. Despite relatively frequent occurrence of vascular
events in untreated homocystinuric patients, only 1.1% of
patients in this large cohort manifested solely with a
vascular symptom. The authors postulated that the observed
incidence of thromboembolism in this disease might be
falsely low because some patients presenting with solely
thromboembolic events and manifesting no other feature of
the CBS deficiency could have remained undiagnosed
(Mudd et al. 1985).
The above hypothesis has been supported by recent
publications describing young adult patients with homo-
cystinuria diagnosed solely on the basis of thromboembolic
events with no other symptoms (Gaustadnes et al. 2000;
Linnebank et al. 2003). In this work, we focused on
examining the frequency of vascular manifestation in
CBS-deficient patients diagnosed in the Czech Republic
over the last three decades.
Methods and patients
All patients have been followed in the Department of
PediatricsandintheInstituteofInheritedMetabolicDisorders
of First Faculty of Medicine of Charles University in Prague.
To our knowledge, the reported 20 patients represent the
absolute majority of Czech patients diagnosed with homo-
cystinuria in the past 30 years.
At least two out of the following three diagnostic criteria
had to be met: (1) metabolic abnormalities (hypermethio-
ninemia with a simultaneous presence of elevated total
plasma homocysteine above 100 μmol/l, or elevated
homocystine in urine and/or free homocystine in blood,
and/or decreased plasma cystathionine), (2) CBS deficiency
in cultured fibroblasts, or (3) the presence of two
pathogenic CBS mutations in cis. Family screening was
carried out in all patients and two affected sib-pairs were
identified (patients 2 and 4, and 8 and 9 in Table 1).
Until 1985, free homocystine was detected in plasma
deproteinated by sulfosalicylic acid using the aminoacid
analyser. Between 1989 and 1993, plasma level of total
homocysteine was determined using the ion-exchange
chromatography after dithiotreitol reduction (Brattström et
al. 1988). Since 1994, high performance liquid chromatog-
raphy (HPLC) with SBDF derivatization has been used to
determine plasma total homocysteine (Araki and Sako
1987; Krijt et al. 2001). The urinary homocystine concen-
tration and plasma methionine level were determined by
ion-exchange chromatography with postcolumn ninhydrine
derivatization. The enzyme activity was measured in
cultured skin fibroblasts radiometrically according to Kraus
(1987). The mutation analysis was carried out using either
genomic DNA and/or RNA isolated from fibroblasts
(Janošík et al. 2001) in all patients except for patient no. 1.
Pyridoxineresponsivenessofpatientswastestedbyanoral
administration of pyridoxine in doses of at least 5–10 mg/kg
per day for at least 2 weeks. Pyridoxine responsive patients
were classified as those with a decrease of plasma total
homocysteine to levels below 50 μmol/l, patients with no
decrease were classified as nonresponders, patients with
intermediate changes as partial responders.
Results
Between 1980 and 2009, a total of 20 Czech patients with
cystathionine beta-synthase deficiency have been diagnosed
in the Czech Republic (Table 1). The number of diagnosed
patients did not differ significantly among the decades—
seven, six and seven patients were diagnosed between 1980
and 1989, between 1990 and 1999, and between 2000 and
2009, respectively. The incidence of clinically diagnosed
patients with CBS deficiency in the Czech Republic was
1:311,000 with the 95% confidence interval of 1:201,000–
1:509,000. The median age at diagnosis was higher in
women (i.e. 15 years), than in men (i.e. 8.5 years).
For each patient, we analyzed the symptoms leading to
the plasma homocysteine level determination, and we
divided the patients into three groups. Patients in the
vascular group were ascertained due to thromboembolic
events and/or thrombophilia screening, or due to intracra-
nial bleeding, while patients in the neurological group were
ascertained due to the delayed psychomotor development.
The symptoms leading to homocysteine analysis in the
connective tissue patient group were myopia, lens ectopia
or marfanoid features.
A vascular event as a clinical feature leading to the
diagnosis of homocystinuria was present in 5 of the 20
patients. Two patients from the vascular group had no other
symptoms typical for CBS deficiency at the time of
diagnosis. All patients ascertained for vascular complication
as the leading symptom have been diagnosed only in the
decade between 2000 and 2009.
The median age at diagnosis was 29 years (range 17–32)
in the vascular group, 11.5 years (range 8–47) in the
connective tissue group and 4.5 years (range 3–16) in the
neurological group. The ratio of pyridoxine responsive to
nonresponsive patients was higher in the vascular (4 of 5
patients) and connective tissue (6 of 7 patients) groups than
in the neurological group (2 of 8 patients).
The mutation analysis revealed a considerable genetic
heterogeneity among Czech patients with CBS deficiency.
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J Inherit Metab Dis (2011) 34:33–37 35The most common CBS mutation c.833T>C (p.I278T) was
frequent in patients with the vascular (6 of 10 alleles) and
connective tissue presentation (8 of 14 alleles), while it was
not present in patients with neurological involvement (none
of 16 alleles; Table 1). As in other populations, the
c.833T>C allele was predominantly detected in Czech
patients with the milder phenotype of CBS deficiency.
Case reports of patients with vascular manifestation
of homocystinuria
Patient no. 14 This woman suffered from abdominal pain
and frequent vomiting in childhood. An episode of left-sided
hemiparesis with impaired consciousness and generalized
seizures appeared at the age of 29 years. Two intra-
parenchymal bleeding lesions in the central cortical area on
the right side were observed on the CT. Subsequent
laboratory analysis revealed plasma total homocysteine level
of 329 μmol/l. No signs of intracranial thrombosis were
detected on digital subtraction angiography.
Patient no. 16 This 32-year-old woman has been treated for
hypothyroidism since 10 years of age. The CBS deficiency
was ascertained due to thrombophilia screening performed
because her first gravidity resulted in spontaneous abortion
3weeks after in vitro fertilization and embryo transfer.At the
time of diagnosis, the patient exhibited moderate myopia.
Patient no. 17 The reason for plasma total homocysteine
analysis in this female patient was the thrombosis of the
sagittal sinus. This was manifested by a sudden headache at
the age of 17 years with focal seizures of the right arm
developing after the event. Since school age, the patient has
been followed up for visual problems—lens subluxation
and myopia–-and for scoliosis.
Patient no. 18 The plasma total homocysteine level in this
19-year-old woman was analysed during the diagnostic
work-up after an ischemic lesion of medial cerebral artery
with a subsequent mild central paresis of the facial nerve
and an integral aphasia. She was on a hormonal contracep-
tion at the time of event. No other symptoms of CBS
deficiency were present at the time of diagnosis.
Patient no. 20 This woman underwent a surgery for
dislocated lenses at the age of 30 years, which was
complicated by thrombosis of the right sigmoideal and
transversal sinuses. Plasma total homocysteine was
analyzed only 2 years later following a delivery of a
dead fetus in the 32nd week of gestation. Scoliosis was
present at the time of diagnosis.
Discussion
Patients ascertained due to vascular events represent a
substantial proportion of Czech patients with homocysti-
nuria. In this subgroup of CBS-deficient patients, the
disease manifested relatively late in life and the course of
the disease was milder than in patients diagnosed due to
neurological or connective tissue symptoms. The observed
proportion of patients diagnosed solely due to vascular
events (2 of 20) was one order of magnitude higher than the
1.1% observed in the large group of Mudd et al. (1985).
The recently observed high number of CBS-deficient
patients with vascular manifestation might be explained by
an increased availability of plasma total homocysteine
measurement in routine thrombophilia screening in the last
decade. This trend is demonstrated by a marked increase in
number of total homocysteine assays in the Czech Republic
between the years 2003–2007 compared to the period of
1998–2002 demonstrated by the data from the largest
national health insurance company (Fig. 1).
Ascertainment of adult patients with CBS deficiency due
to vascular events has been reported in the past decade also
by other authors. Gaustadnes et al. (2000) described three
CBS deficient sisters aged 58, 56 and 55, respectively, who
manifested by repeated vascular events since the third
decade of life. Ophtalmologic examination revealed no lens
ectopia or other visual problems, the mental state of the
patients was normal and none of the three patients had
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Fig. 1 Number of total homo-
cysteine assays between 1998
and 2007. Data provided by the
Všeobecná zdravotní pojišťovna
(VZP) which provides health
insurance for 65–75% of the
population of the Czech Republic
36 J Inherit Metab Dis (2011) 34:33–37reduced bone mineral content as determined by dual-energy
X-ray absorptiometric scanning at the time of diagnosis.
Linnebank et al. (2003) screened for the c.833T>C allele in
225 DNA samples of young adults with ischemic stroke
and in 46 samples of patients with sinus thrombosis. They
found a 34-year-old male who suffered from bilateral
occlusion of the carotid arteries and of one vertebral artery,
and with three previously documented stroke episodes. The
second patient was a 24-year-old woman who developed
thromboembolic symptoms after delivery of a healthy
daughter via Ceasarian section. These two patients did not
present any other nonvascular symptoms of homocystinuria.
All the patients with only vascular manifestation
presented by Gaustadnes and Linnebank (Gaustadnes
et al. 2000; Linnebank et al. 2003) were homozygotes for
the c.833T>C allele. The high frequency of c.833T>C was
also seen in our patients manifesting with vascular events.
Recently, Skovby et al. (2010) observed a large difference
between the number of diagnosed Danish homocystinuric
patients and the incidence of predicted homozygosity for
the c.833T>C allele (1:20,400; 95% CI 1:4,800–
1:128,000). Only 10 patients were diagnosed in contrast
to about 270 such individuals that were expected based on
the molecular screening of the Danish population (95% CI
43–1,148). Two of those 10 patients were clinically
unaffected and diagnosed by family screening because of
an affected sibling (Skovby et al. 2010). The large
discrepancy between the number of diagnosed homocysti-
nuric patients compared to a predicted frequency of
homozygosity was also seen in the Czech population
(Sokolová et al. 2001;J a n o šík et al. 2009). These studies
and our observation of patients with CBS deficiency
diagnosed in adulthood support the hypothesis proposed by
Skovby et al. (2010) that the predominant portion of
homozygotes for the c.833T>C allele may be clinically
unaffected, or may be ascertained for thromboembolic events
occurring no sooner than in the third decade of life.
Conclusion
Vascular manifestation was a leading symptom initiating
diagnostic work-up in one-quarter of Czech patients with
CBS deficiency. These patients have been diagnosed due to
vascular complications only in the last decade, and it can be
hypothesized that this was most likely due to the increased
availability of plasma homocysteine determination. This
milder form of the disease usually manifested at a greater
age, had a high ratio of pyridoxine responsiveness, and the
mutation c.833T>C (p.I278T) was often present. Observa-
tion of a high proportion of patients with a vascular
presentation of the disease emphasizes the importance of
the total homocysteine plasma level determination in
patients with thromboembolic events in adulthood.
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